C4 therapeutics announces fda clearance of investigational new drug application for cft8919, an orally bioavailable bidac™ degrader targeting egfr l858r for non-small cell lung cancer

Watertown, mass., july 05, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (tpd) science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) application for cft8919, an orally bioavailable bidac™ degrader designed to be potent and selective against egfr l858r for non-small cell lung cancer (nsclc) patients.
CCCC Ratings Summary
CCCC Quant Ranking